Heini, A.D.; Kammermann, K.; Bacher, U.; Jeker, B.; Hayoz, M.; Aebi, Y.; Largiadèr, C.R.; Nilius, H.; Pabst, T.
Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma. Cancers 2024, 16, 3364.
https://doi.org/10.3390/cancers16193364
AMA Style
Heini AD, Kammermann K, Bacher U, Jeker B, Hayoz M, Aebi Y, Largiadèr CR, Nilius H, Pabst T.
Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma. Cancers. 2024; 16(19):3364.
https://doi.org/10.3390/cancers16193364
Chicago/Turabian Style
Heini, Alexander D., Karin Kammermann, Ulrike Bacher, Barbara Jeker, Michael Hayoz, Yolanda Aebi, Carlo R. Largiadèr, Henning Nilius, and Thomas Pabst.
2024. "Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma" Cancers 16, no. 19: 3364.
https://doi.org/10.3390/cancers16193364
APA Style
Heini, A. D., Kammermann, K., Bacher, U., Jeker, B., Hayoz, M., Aebi, Y., Largiadèr, C. R., Nilius, H., & Pabst, T.
(2024). Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma. Cancers, 16(19), 3364.
https://doi.org/10.3390/cancers16193364